Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$0.08 USD
+0.02 (22.82%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $0.08 0.00 (-2.20%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ADAP 0.08 +0.02(22.82%)
Will ADAP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ADAP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ADAP
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Crossed Above 20 Day Moving Average appears for ADAP after 18.93% move
Is ADAP ready to move higher? Pocket Pivot shows up after rallying 10.89%
Is ADAP set to breakout? NR7 shows up after sinking 0.59%